X4 Pharmaceuticals (XFOR) EPS (Basic) Growth (1y) (2018 - 2026)
Powered by 
Analysis
X4 Pharmaceuticals (XFOR) EPS (Basic) Growth (1y) (2018 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 663.08 Bn | 642.33 Bn | 17.26 Bn | -0.10% |
| 2 | AbbVie | 453.04 Bn | 446.51 Bn | 12.70 Bn | 284.05% |
| 3 | Merck | 370.87 Bn | 363.78 Bn | 12.21 Bn | -130.68% |
| 4 | Novartis Ag | 305.29 Bn | 298.00 Bn | 11.24 Bn | -15.94% |
| 5 | Pfizer | 162.10 Bn | 150.70 Bn | 10.94 Bn | -108.11% |
| 6 | Sanofi | 53.95 Bn | 46.98 Bn | 10.79 Bn | -91.06% |
| 7 | Revolution Medicines | 45.00 Bn | 45.00 Bn | - | - |
| 8 | BeOne Medicines | 40.49 Bn | 35.39 Bn | 1.53 Bn | 143.95% |
| 9 | Incyte | 25.47 Bn | 20.94 Bn | 1.57 Bn | 39.99% |
| 10 | X4 Pharmaceuticals | 510.43 Mn | 315.33 Mn | 7.19 Mn | 96.32% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 96.32% |
| Mar 31, 2026 | -497.46% |
| Dec 31, 2025 | 90.48% |
| Sep 30, 2025 | 87.42% |
| Jun 30, 2025 | -866.60% |
| Mar 31, 2025 | 115.58% |
| Dec 31, 2024 | -5,423.79% |
| Sep 30, 2024 | -46,681.17% |
| Jun 30, 2024 | 237.24% |
| Mar 31, 2024 | -57.40% |
| Dec 31, 2023 | 76.52% |
| Sep 30, 2023 | 95.55% |
| Jun 30, 2023 | 44.84% |
| Mar 31, 2023 | 77.08% |
| Dec 31, 2022 | 67.15% |
| Sep 30, 2022 | 65.33% |
| Jun 30, 2022 | 19.14% |
| Mar 31, 2022 | 44.64% |
| Dec 31, 2021 | -52.18% |
| Sep 30, 2021 | 12.73% |